索磷布韦/维帕他韦用于经治丙型肝炎病毒感染患者——简短报告
Sofosbuvir/velpatasvir in treatment-experienced HCV-infected patients - short report.
作者信息
Piekarska Anna, Berkan-Kawińska Aleksandra, Deroń Zbigniew, Ciupińska Justyna, Białkowska Jolanta
机构信息
Department of Infectious Diseases and Hepatology, Medical University of Lodz, Poland.
Department of Infectious Diseases and Liver Diseases, WSSz Bieganski, Lodz, Poland.
出版信息
Clin Exp Hepatol. 2020 Feb;6(1):60-62. doi: 10.5114/ceh.2020.93059. Epub 2020 Feb 17.
AIM OF THE STUDY
The aim of this overview was to evaluate the efficacy of sofosbuvir/velpatasvir (SOF/VEL) combination in a real-life setting, with particular regard to treatment-experienced individuals.
MATERIAL AND METHODS
Seventy-five consecutive patients who were treated with SOF/VEL, completed the 12-week follow-up and had sustained virologic response (SVR) evaluated were included in the analysis. Out of them, 60 (80%) patients were treatment-naïve and 15 (20%) were treatment-experienced.
RESULTS
SVR rates reached 89.4% (66/75) in the whole study group and were comparable irrespective of the fibrosis stage or HCV genotype. However, a significant difference in treatment efficacy between treatment-naïve and treatment-experienced individuals was observed, with SVR rates of 98.3% (59/60) and 46.7% (7/15), respectively ( < 0.0001).
CONCLUSIONS
Further studies including large real-life cohorts of treatment-experienced patients treated with SOF/VEL are warranted to elucidate the real efficacy of this regimen as a retreatment option.
研究目的
本综述的目的是评估索磷布韦/维帕他韦（SOF/VEL）组合在实际临床环境中的疗效，尤其关注经治患者。
材料与方法
分析纳入了75例连续接受SOF/VEL治疗、完成12周随访且评估有持续病毒学应答（SVR）的患者。其中，60例（80%）患者为初治患者，15例（20%）为经治患者。
结果
整个研究组的SVR率达到89.4%（66/75），且无论纤维化阶段或HCV基因型如何，SVR率均相当。然而，初治患者和经治患者之间的治疗疗效存在显著差异，SVR率分别为98.3%（59/60）和46.7%（7/15）（<0.0001）。
结论
有必要开展进一步研究，纳入接受SOF/VEL治疗的大量实际临床经治患者队列，以阐明该方案作为再治疗选择的实际疗效。
Zotero 插件